|
Imiquimod VacciGrade™
Imidazoquinoline compound
The imidazoquinoline compound Imiquimod is a guanosine derivative and agonist for TLR7.
This TLR7 agonist, originally developed as type I IFN inducers, is an effective adjuvant by activating dendritic cells (DCs) and B cells to induce cytokines optimal for Th1 cell immunity, and antibody production.
Unlike other commercially available Imiquimod preparations, InvivoGen's Imiquimod VacciGrade™ is controlled for TLR7/8 potency and TLR4/TLR2 contamination.
Imiquimod VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.
Imiquimod VacciGrade™ is for research use only, not for use in humans.
Specificity: Th1 response
Working concentration: 10 - 100 μg/mouse
Endotoxin level: <5 EU/mg (limit of detection)
Solubility: 1 mg/ml in physiological water |